TREATMENT WITH A HUMANIZED ANTI-EGFR IgG1 ANTIBODY AND IRINOTECAN
OwnerThomas Friess, Ekkehard Moessner +2inventors
InventorsThomas Friess, Ekkehard Moessner, Samuel Moser, Pablo Umana
Life of this patent
Estimating the term…
Abstract
The present invention provides a humanized anti-EGFR IgG1 antibody and irinotecan for combined use in treating cancer, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy. The invention also encompasses a pharmaceutical composition that is comprised of a combination of a humanized anti-EGFR IgG1 antibody and irinotecan in a pharmaceutically acceptable carrier, and methods for the treatment of cancer comprising administering both irinotecan and a humanized anti-EGFR IgG1 antibody.
Claims14
A pharmaceutical composition comprising a humanized anti-EGFR IgG1 antibody, irinotecan, and a pharmaceutically acceptable carrier, wherein said humanized anti-EGFR IgG1 antibody comprises:
- a) in the heavy chain variable domain a CDR1 with the amino acid sequence set forth in SEQ ID NO:1, a CDR2 with the amino acid sequence set forth in SEQ ID NO:16, and a CDR3 with the amino acid sequence set forth in SEQ ID NO:31;
- and
- b) in the light chain variable domain a CDR1 with the amino acid sequence set forth in SEQ ID NO:33, a CDR2 with the amino acid sequence set forth in SEQ ID NO:34, and a CDR3 with the amino acid sequence set forth in SEQ ID NO:35,
- and wherein the humanized anti-EGFR IgG1 antibody comprises an Fc-region comprising oligosaccharides.
A kit for use in the treatment of cancer comprising irinotecan and a humanized anti-EGFR IgG1 antibody, where in the irinotecan and the humanized anti-EGFR IgG1 antibody are in the same or in separate containers, wherein said humanized anti-EGFR IgG1 antibody comprises
- a) in the heavy chain variable domain a CDR1 with the amino acid sequence set forth in SEQ ID NO:1, a CDR2 with the amino acid sequence set forth in SEQ ID NO:16, and a CDR3 with the amino acid sequence set forth in SEQ ID NO:31;
- and
- b) in the light chain variable domain a CDR1 with the amino acid sequence set forth in SEQ ID NO:33, a CDR2 with the amino acid sequence set forth in SEQ ID NO:34, and a CDR3 with the amino acid sequence set forth in SEQ ID NO:35,
- and wherein the humanized anti-EGFR IgG1 antibody comprises an Fc-region comprising oligosaccharides.
A method for the treatment of cancer, comprising administering to a subject in need of such treatment a therapeutically effective amount of a combination of a humanized anti-EGFR IgG1 antibody and irinotecan, wherein said humanized anti-EGFR IgG1 antibody comprises
- a) in the heavy chain variable domain a CDR1 with the amino acid sequence set forth in SEQ ID NO:1, a CDR2 with the amino acid sequence set forth in SEQ ID NO:16, and a CDR3 with the amino acid sequence set forth in SEQ ID NO:31;
- and
- b) in the light chain variable domain a CDR1 with the amino acid sequence set forth in SEQ ID NO:33, a CDR2 with the amino acid sequence set forth in SEQ ID NO:34, and a CDR3 with the amino acid sequence set forth in SEQ ID NO:35,
- and wherein the humanized anti-EGFR IgG1 antibody comprises an Fc-region comprising oligosaccharides.
Dependencies are inferred from the claim text.